01. Why this comparison remains available
AFTERBURN is a retired bundle name. This page remains available as a research comparison; it does not describe a currently available bundle, included accessories or promotional entitlement.
RETROD is MGMT Research’s name for retatrutide research material; TESAROSSA is its name for tesamorelin research material. Clinical findings concern the study formulations and populations, not the quality or suitability of separately supplied research vials.
02. RETROD: the retatrutide research profile
Retatrutide activates GLP-1, GIP and glucagon receptors. In a 338-participant phase 2 obesity study, the 12 mg study group had a mean body-weight reduction of 17.5% at 24 weeks and 24.2% at 48 weeks, compared with 1.6% and 2.1% with placebo. [1]
Those are body-weight outcomes from a supervised trial—not a measurement of pure fat loss, an overnight result or evidence for combining these compounds.
03. TESAROSSA: the tesamorelin research profile
Tesamorelin is a growth hormone-releasing hormone analogue. It stimulates growth hormone release and increases IGF-1. Its clinical evidence includes reducing excess abdominal fat in adults with HIV-associated lipodystrophy. [2]
The U.S. EGRIFTA WR label specifically states that the medicine is not indicated for weight-loss management and has a weight-neutral effect. That distinction matters when comparing tesamorelin findings with retatrutide weight-loss results. [2]
TESAROSSA is a research product. It is not the approved prescription formulation described in that label, and the label does not establish interchangeable dosing or preparation instructions.
A 26-week randomized trial enrolled 412 people with HIV and excess abdominal fat and measured visceral fat by CT. That population and outcome differ from general-obesity body-weight studies. [3]
04. Two pathways do not prove a combined benefit
The scientific interest is understandable: the compounds act through different hormonal pathways and have been studied using different outcomes. That can motivate a research question, but it does not answer it.
The cited studies evaluated the compounds separately; they do not establish efficacy, safety or a dosing regimen for their combination. We therefore do not add their percentages together or present a combined schedule as validated.
05. Scale weight, visceral fat and body composition
| Measurement | What it describes | What it cannot establish alone |
|---|---|---|
| Body weight | Total measured mass | How much of a change is fat, fluid or lean tissue |
| Visceral fat | Fat within the abdominal cavity | The same percentage change in total body weight |
| Waist circumference | An external body measurement | A direct measurement of visceral fat volume |
| Body composition | Estimated or measured tissue compartments | Proof that a particular combination caused the change |
A bathroom scale is useful for recording weight. Its reading should not be presented as direct proof of visceral-fat reduction or preservation of muscle.
06. Safety considerations belong in the comparison
Retatrutide’s phase 2 study reported dose-related gastrointestinal adverse events and increases in heart rate. [1]
Tesamorelin prescribing information includes warnings about elevated IGF-1, fluid retention, glucose intolerance or diabetes, and hypersensitivity. It also lists contraindications including active malignancy and pregnancy. This is not an exhaustive list. [2]
Different mechanisms do not mean the compounds’ risks cancel each other out. Separate safety data cannot establish that combined use is safe. Questions about personal treatment, interactions or symptoms require a qualified healthcare professional.
07. Laboratory handling and batch documentation
Keep each compound clearly identified with its own lot, quantity, preparation record and concentration. A shared storage location does not establish that two materials are compatible or should be mixed.
Bacteriostatic water is a diluent, not evidence of compatibility or a combined treatment benefit. Use only a validated, compatible laboratory procedure and follow the actual storage and handling instructions. A generic online guide cannot assign a universal post-mixing shelf life.
Our calculator checks laboratory volume arithmetic. It does not select a human dose or confirm that two materials can be mixed.
Refer to COA & Batch Reports for the actual report and status of each compound lot. A pending report is not completed testing.
08. Frequently asked questions
Do separate trials validate a combined treatment?
No. A benefit for one compound in one population does not establish the benefit, safety or regimen of a combination.
Can I add weight-loss and visceral-fat percentages?
No. They describe different outcomes and populations. Adding them would create an unsupported result.
Does tesamorelin evidence apply to general weight-loss management?
The cited U.S. EGRIFTA WR label concerns excess abdominal fat in adults with HIV-associated lipodystrophy and explicitly excludes weight-loss management. It does not establish equivalence to TESAROSSA research material. [2]
Is AFTERBURN still offered?
The bundle is retired. Refer to the current collection for available products.
09. Sources and related guides
- Peer-reviewed studyJastreboff et al. Retatrutide phase 2 obesity trial. NEJM, 2023.
- Manufacturer labelingDailyMed: EGRIFTA WR (tesamorelin) prescribing information.
- Peer-reviewed studyFalutz et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM, 2007. DOI: 10.1056/NEJMoa072375.